Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Background: Over the last two decades, a number of studies have highlighted the potential of psychedelic therapy. However, questions remain to what extend these results translate to naturalistic samples, and how contextual factors and the acute psychedelic experience relate to improvements in affective symptoms following psychedelic experiences outside labs/clinics. The present study sought to address this knowledge gap. Aim: Here, we aimed to investigate changes in anxiety and depression scores before versus after psychedelic experiences in naturalistic contexts, and how various pharmacological, extrapharmacological and experience factors related to outcomes. Method: Individuals who planned to undergo a psychedelic experience were enrolled in this online survey study. Depressive symptoms were assessed at baseline and 2 and 4 weeks post-psychedelic experience, with self-rated Quick Inventory of Depressive Symptomatology (QIDS-SR-16) as the primary outcome. To facilitate clinical translation, only participants with depressive symptoms at baseline were included. Sample sizes for the four time points were N = 302, N = 182, N = 155 and N = 109, respectively. Results: Relative to baseline, reductions in depressive symptoms were observed at 2 and 4 weeks. A medicinal motive, previous psychedelic use, drug dose and the type of acute psychedelic experience (i.e. specifically, having an emotional breakthrough) were all significantly associated with changes in self-rated QIDS-SR-16. Conclusion: These results lend support to therapeutic potential of psychedelics and highlight the influence of pharmacological and non-pharmacological factors in determining response. Mindful of a potential sample and attrition bias, further controlled and observational longitudinal studies are needed to test the replicability of these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 2×
“The primary outcome was change in severity of depressive symptoms measured by the QIDS-SR-16 henceforth abridged to just the ‘Quick Inventory of Depressive Symptomatology (QIDS)’ (Rush et al., 2003) from baseline to 2 and 4 weeks after a self-initiated psychedelic experience – ‘postexperience’.”
MethodMarteau, T. M., & Bekker, H. (1992) · British Journal of Clinical Psychology · doi:10.1111/j.2044-8260.1992.tb00997.x · Cited by 3,238 · cited 2×
“The measurement is derived from the widely used 20-item Spielberger State-Trait Anxiety Inventory (STAI) and has shown to possess satisfactory concurrent validity (Marteau and Bekker, 1992).”
MethodGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 7×
“Notably, improvements in symptom severity have been observed several months after just one or two isolated doses of the drug (Carhart-Harris et al., 2017, 2021a; Davis et al., 2021a; Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011).”
BackgroundResultInfluentialRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationTrial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391 · cited 7×
“Notably, improvements in symptom severity have been observed several months after just one or two isolated doses of the drug (Carhart-Harris et al., 2017, 2021a; Davis et al., 2021a; Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011).”
BackgroundResultSelf-citationEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301 · cited 9×
“Notably, improvements in symptom severity have been observed several months after just one or two isolated doses of the drug (Carhart-Harris et al., 2017, 2021a; Davis et al., 2021a; Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011).”
BackgroundResultInfluentialPilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 5×
“Notably, improvements in symptom severity have been observed several months after just one or two isolated doses of the drug (Carhart-Harris et al., 2017, 2021a; Davis et al., 2021a; Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011).”
BackgroundInfluentialHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 3×
“Unlike in previous studies (Bogenschutz et al., 2015; Davis et al., 2019; Erritzoe et al., 2018; Griffiths et al., 2008, 2016; Haijen et al., 2018; MacLean et al., 2011; Nour et al., 2017; Schmid and Liechti, 2017), the MEQ was not significantly predictive of response in this study.”
BackgroundResultPsilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970 · cited 6×
“Notably, improvements in symptom severity have been observed several months after just one or two isolated doses of the drug (Carhart-Harris et al., 2017, 2021a; Davis et al., 2021a; Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011).”
BackgroundMethodResultInfluentialSelf-citationPsilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852 · cited 4×
“…and anxiety symptoms and disorders (Barbosa et al., 2016; Carhart-Harris et al., 2017, 2021a, 2021b; Davis et al., 2021a; Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011; Moreno et al., 2006; Osório et al., 2015; Palhano-Fontes et al., 2019; Ross et al., 2016; Sanches et al., 2016).”
BackgroundInfluentialRoseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Self-citationSafety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 3×
“…and anxiety symptoms and disorders (Barbosa et al., 2016; Carhart-Harris et al., 2017, 2021a, 2021b; Davis et al., 2021a; Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011; Moreno et al., 2006; Osório et al., 2015; Palhano-Fontes et al., 2019; Ross et al., 2016; Sanches et al., 2016).”
BackgroundGasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · cited 5×
“Notably, improvements in symptom severity have been observed several months after just one or two isolated doses of the drug (Carhart-Harris et al., 2017, 2021a; Davis et al., 2021a; Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011).”
BackgroundInfluentialPsychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657 · cited 6×
“Consistent with previous findings and current and long-standing assumptions about the context-dependency of psychedelic outcomes (Carhart-Harris et al., 2018; Haijen et al., 2018; Hartogsohn, 2017; Leary et al., 1963; Metzner et al., 1965; Studerus et al., 2012), having medicinal motives for use was associated with la…”
BackgroundResultInfluentialSelf-citationValidation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637
Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817709585 · Cited by 589 · cited 3×
“These trials supplement a number of lab-based experimental studies conducted in the last 10 years that have found consistent positive results in favour of the therapeutic potential of psychedelic therapy for treating symptoms of depression and anxiety (Carhart-Harris et al., 2016a, 2017; Davis, Barrett and May, 2021;…”
BackgroundSelf-citationGriffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117731279 · Cited by 520
Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517 · cited 1×
“…doses are more likely to produce the intensity and quality of acute experience (Griffiths et al., 2011; Haijen et al., 2018; Hasler et al., 2004; Madsen et al., 2019; Studerus et al., 2012) that seems to be important (if not necessary) for robust therapeutic outcomes (Carbonaro et al., 2016;…”
BackgroundPsilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Constructing drug effects: a history of set and setting
Hartogsohn, I. (2017) · Drug Science Policy and Law · doi:10.1177/2050324516683325 · Cited by 472 · cited 2×
“…and current and long-standing assumptions about the context-dependency of psychedelic outcomes (Carhart-Harris et al., 2018; Haijen et al., 2018; Hartogsohn, 2017; Leary et al., 1963; Metzner et al., 1965; Studerus et al., 2012), having medicinal motives for use was associated with larger…”
BackgroundSanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466 · cited 4×
“These trials supplement a number of lab-based experimental studies conducted in the last 10 years that have found consistent positive results in favour of the therapeutic potential of psychedelic therapy for treating symptoms of depression and anxiety (Carhart-Harris et al., 2016a, 2017; Davis, Barrett and May, 2021;…”
BackgroundInfluentialHasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Predicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417
Self-citationEmotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855974 · Cited by 413 · cited 17×
“Having an emotional breakthrough is often accompanied by personal and interpersonal psychological insights (Roseman et al., 2019).”
BackgroundSelf-citationDavis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375 · cited 14×
“…are associated with positive therapeutic outcomes in relation to depression and anxiety (Davis et al., 2020), racial trauma (Williams et al., 2021) and alcohol abuse (GarciaRomeu et al., 2019) and that psychological flexibility seem to mediate effects (Davis et al., 2020; Williams et al., 2021).”
BackgroundMethodInfluentialPrediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369 · cited 18×
“…of music (Kaelen et al., 2015), other people (Kettner et al., 2021), non-defined ‘distractions’ (Haijen et al., 2018), whether the psychedelic is taken in a structured and supportive environment (Sepeda et al., 2020) and whether it is taken in a neuroimaging setting (Studerus et al., 2012).”
BackgroundInfluentialBarrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116678781 · Cited by 366 · cited 5×
“High ratings for CE have been associated with both worsened (Barrett et al., 2016; Carbonaro et al., 2016; Haijen et al., 2018; Roseman et al., 2018) and improved long-term mental health outcomes (Carbonaro et al., 2016; Davis et al., 2021b).”
BackgroundInfluentialThe paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293 · cited 3×
“…baseline to 2-week follow-up were found to be large by convention (Cohen’s d = 1.2) and were comparable to those seen in controlled studies (e.g. Carhart-Harris et al., 2016a, 2017) when assessing a comparably severe subsample, that is, Cohen’s d of 2.1–2.4 in those with moderate-to-severe…”
BackgroundMethodResultInfluentialSelf-citationEffects of psilocybin therapy on personality structure
Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart‐Harris, R. L. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12904 · Cited by 267
Self-citationTherapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression
Murphy, R., Kettner, H., Zeifman, R., Giribaldi, B., Kartner, L., Martell, J., Read, T., Murphy-Beiner, A., Baker-Jones, M., Nutt, D., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.788155 · Cited by 250 · cited 4×
“Specifically, a number of studies have found that ‘peak’ or ‘mystical’ – type experiences, which feature feelings of unity, transcendence of time, space and self, and positive mood, are predictive of subsequent positive therapeutic outcomes (Bogenschutz et al., 2015; Davis et al., 2019; Garcia-Romeu et al., 2015; Grif…”
BackgroundSelf-citationLong-lasting subjective effects of LSD in normal subjects.
Schmid, Y., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4733-3 · Cited by 232 · cited 5×
“Given the consistent performance of the MEQ as mediator of therapeutic outcomes in a range of populations (Bogenschutz et al., 2015; Davis et al., 2019; Erritzoe et al., 2018; Griffiths et al., 2008, 2016; Haijen et al., 2018; MacLean et al., 2011; Nour et al., 2017; Schmid and Liechti, 2017), we do not advocate aband…”
BackgroundResultInfluentialPsychedelics, personality and political perspectives.
Nour, M. M., Evans, L., & Carhart-Harris, R. L. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1312643 · Cited by 226
Self-citationAday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K., & Davoli, C. C. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00014 · Cited by 224 · cited 14×
“, 2022), as well as apprehensive and confused psychological states (Aday et al., 2021).”
BackgroundInfluentialKettner, H., Rosas, F. E., Timmermann, C., Kärtner, L., Carhart-Harris, R. L., & Roseman, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623985 · Cited by 221
Self-citationSelf-blinding citizen science to explore psychedelic microdosing
Szigeti, B., Kartner, L., Blemings, A., Rosas, F., Feilding, A., Nutt, D. J., Carhart-Harris, R. L., & Erritzoe, D. (2021) · eLife · doi:10.7554/elife.62878 · Cited by 192
Reilly, T. J., MacGillivray, S. A., Reid, I. C., & Cameron, I. M. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.09.008 · Cited by 155 · cited 1×
“Using established cut-off values (Reilly et al., 2015), QIDS scores were used to divide participants into separate four groups with regard to presence/severity of depression: 0–5 (none), 6–10 (mild), 11–15 (moderate) and 16–27 (severe/very severe).”
MethodPositive expectations predict improved mental-health outcomes linked to psychedelic microdosing
Kaertner, L. S., Steinborn, M. B., Kettner, H., Spriggs, M. J., Roseman, L., Buchborn, T., Balaet, M., Timmermann, C., Erritzoe, D., & Carhart-Harris, R. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-81446-7 · Cited by 145 · cited 1×
“Positive expectancy has recently come under the spotlight in psychedelic research where for example, belief about receipt of a psychedelic appears to be major driver of outcomes (Kaertner et al., 2021; Olson et al., 2020; Szigeti et al., 2021; Van Elk et al., 2021).”
BackgroundDavis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1545024 · Cited by 142 · cited 6×
“Given the consistent performance of the MEQ as mediator of therapeutic outcomes in a range of populations (Bogenschutz et al., 2015; Davis et al., 2019; Erritzoe et al., 2018; Griffiths et al., 2008, 2016; Haijen et al., 2018; MacLean et al., 2011; Nour et al., 2017; Schmid and Liechti, 2017), we…”
BackgroundResultInfluentialPeill, J. M., Trinci, K. E., Kettner, H., Mertens, L. J., Roseman, L., Timmermann, C., Rosas, F. E., Lyons, T., & Carhart-Harris, R. L. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211066709 · Cited by 141 · cited 11×
“…in our recent double-blind randomised controlled trial, sub-acute psychological insight was found to mediate the relationship between emotional breakthrough and improvements in depression – using a new scale to measure insight that is, the psychological insight scale (PIS) (Peill et al., 2022).”
BackgroundMethodSelf-citationAgin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00018 · Cited by 124 · cited 2×
“, 2012) and subsequent longer-term outcomes linked to psychedelic use (Agin-Liebes et al., 2021; Davis et al., 2021a; Garcia-Romeu et al., 2015; Griffiths et al., 2018; Haijen et al., 2018; MacLean et al., 2011; Palhano-Fontes et al., 2019; Roseman et al., 2018; Sepeda et al., 2020; Williams et al., 2021).”
BackgroundPsychological and neuropsychological assessment of regular hoasca users
Barbosa, P. C. R., Strassman, R. J., da Silveira, D. X., Areco, K., Hoy, R., Pommy, J., Thoma, R., & Bogenschutz, M. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.09.003 · Cited by 105 · cited 2×
“…psychedelicassisted therapy has begun to accrue promising results, particularly in the treatment of depressive and anxiety symptoms and disorders (Barbosa et al., 2016; Carhart-Harris et al., 2017, 2021a, 2021b; Davis et al., 2021a; Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011;…”
BackgroundSpriggs, M. J., Kettner, H., & Carhart-Harris, R. L. (2021) · Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity · doi:10.1007/s40519-020-01000-8 · Cited by 105 · cited 2×
“Indeed, we have now seen this in both healthy participants (Roseman et al., 2019), individuals with eating disorders (Spriggs et al., 2020) and individuals with depression in a recent controlled trial.”
BackgroundSelf-citationWilliams, M. T., Davis, A. K., Xin, Y., Sepeda, N. D., Grigas, P. C., Sinnott, S., & Haeny, A. M. (2021) · Drugs: Education, Prevention and Policy · doi:10.1080/09687637.2020.1854688 · Cited by 101 · cited 4×
“…and subsequent longer-term outcomes linked to psychedelic use (Agin-Liebes et al., 2021; Davis et al., 2021a; Garcia-Romeu et al., 2015; Griffiths et al., 2018; Haijen et al., 2018; MacLean et al., 2011; Palhano-Fontes et al., 2019; Roseman et al., 2018; Sepeda et al., 2020; Williams et al., 2021).”
BackgroundInfluentialDavis, A. K., Xin, Y., Sepeda, N. D., Garcia-Romeu, A., & Williams, M. T. (2021) · Chronic Stress · doi:10.1177/24705470211035607 · Cited by 67 · cited 9×
“Notably, improvements in symptom severity have been observed several months after just one or two isolated doses of the drug (Carhart-Harris et al., 2017, 2021a; Davis et al., 2021a; Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011).”
BackgroundResultInfluentialStauffer, C. S., Anderson, B. T., Ortigo, K. M., & Woolley, J. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00169 · Cited by 65
Carhart-Harris, R. L., Wagner, A. C., Agrawal, M., Kettner, H., Rosenbaum, J. F., Gazzaley, A., Nutt, D. J., & Erritzoe, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211008567 · Cited by 51
Self-citationHjorth, O. R., Frick, A., Gingnell, M., Hoppe, J. M., Faria, V., Hultberg, S., Alaie, I., Månsson, K. N. T., Rosén, J., Reis, M., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01682-3 · Cited by 46
Cited by
Brewerton, T. D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1149433 · Cited by 46
Brewerton, T. D., Gavidia, I., Suro, G., & Perlman, M. M. (2023) · Journal of Eating Disorders · doi:10.1186/s40337-023-00773-4 · Cited by 38
Rethinking the role of TRKB in the action of antidepressants and psychedelics
Brunello, C. A., Cannarozzo, C., & Castrén, E. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.08.011 · Cited by 31
Metadata
- Authors
- Nygart, V. A., Pommerencke, L. M., Haijen, E., Kettner, H., Kaelen, M., Mortensen, E. L., Nutt, D. J., Carhart-Harris, R. L., & Erritzoe, D.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2022-08
- Volume
- 36
- Issue
- 8
- Pages
- 932-942
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W4289841582
- Cited by
- 73
- References
- 52
- FWCI
- 13.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.